Overview
B&K CORP-B (2396)
B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and ma...
- Open
- 3.575
- High
- 3.575
- Low
- 3.215
- Prev. Close
- 3.500
- Volume
- 4.40K
- Turnover
- 14.77K
- Avg Price
- 3.356
- Bid/Ask Ratio
- -73.33%
- Amplitude
- 10.29%
- 52wk High
- 37.200
- Volume Ratio
- 0.36
- Turnover Ratio
- 0.01%
- 52wk Low
- 3.005
- HK Mkt Cap
- 282.28M
- Market CapHKD
- 400.04M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -2.39
- EPSDynamic
- -2.39
- EPSStatic
- --
- BVPS
- 5.44
- P/B
- 0.62
- HK Shares
- 83.02M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 117.66M
- Min lot size
- 200
- Currency
- HKD
Daily Events
- Jul, 3
B&K Corporation staged a sharp intraday reversal, opening lower but rallying in the afternoon session to close at HKD 4.300, up 5.65% from the previous close, with an intraday swing of 11.69% after hitting a 52-week low of HKD 3.850. The stock, which has plunged 88.44% from its 52-week high of HKD 37.2 and is down 73.16% YTD, remains below its 20-day (HKD 4.546) and 60-day (HKD 5.771) moving averages. The rebound was driven by news that the company enrolled its first patient in a Phase IIIa trial for a key burn treatment, alongside a 109.06% YoY revenue surge to approximately HKD 580,000 in Q4 2025, though its net loss widened to HKD 82.9 million. However, trading volume remained thin at 50,400 shares, with a turnover rate of just 0.06%.
- Jul, 2
华芢生物-B 今日低开探底后小幅回升,收盘报 4.05 港元,跌 0.7%,主要因公司基本面持续承压且股价仍处弱势区间。盘中最低触及 3.62 港元,逼近 52 周低点 3.61 港元,距 52 周高点 37.20 港元跌幅达 89.1%;YTD 累计跌 74.7%,均线系统呈空头排列(MA20 4.60/MA60 5.83)。财报显示 Q4 2025 营收同比增 109% 至 58 万港元,但净亏损扩大 61.8% 至 8286 万港元,每股亏损 0.81 港元,盈利能力未见改善。消息面上,针对烧伤的 IIIa 期临床已启动首例入组,全年股东大会通过治理及资本授权决议。不过,全日成交仅 6000 股、换手率 0.01%,显示缺乏资金关注。
